Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Frontiers in clinical drug research CNS and neurological disorders . Volume 7 / / edited by Atta-ur-Rahman and Zareen Amtul
| Frontiers in clinical drug research CNS and neurological disorders . Volume 7 / / edited by Atta-ur-Rahman and Zareen Amtul |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] |
| Descrizione fisica | 1 online resource (166 pages) |
| Disciplina | 615.7 |
| Collana | Frontiers in Clinical Drug Research |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations |
| ISBN | 981-14-4752-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910794360203321 |
| Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research CNS and neurological disorders . Volume 7 / / edited by Atta-ur-Rahman and Zareen Amtul
| Frontiers in clinical drug research CNS and neurological disorders . Volume 7 / / edited by Atta-ur-Rahman and Zareen Amtul |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] |
| Descrizione fisica | 1 online resource (166 pages) |
| Disciplina | 615.7 |
| Collana | Frontiers in Clinical Drug Research |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations |
| ISBN | 981-14-4752-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910810341003321 |
| Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research . Volume 6 CNS and neurological disorders / / edited by Attar-ur-Rahman
| Frontiers in clinical drug research . Volume 6 CNS and neurological disorders / / edited by Attar-ur-Rahman |
| Pubbl/distr/stampa | Sharjah, UAE : , : Bentham Science Publishers, , [2018] |
| Descrizione fisica | 1 online resource (218 pages) |
| Disciplina | 615.7 |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations |
| ISBN | 1-68108-607-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910793110103321 |
| Sharjah, UAE : , : Bentham Science Publishers, , [2018] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research . Volume 6 CNS and neurological disorders / / edited by Attar-ur-Rahman
| Frontiers in clinical drug research . Volume 6 CNS and neurological disorders / / edited by Attar-ur-Rahman |
| Pubbl/distr/stampa | Sharjah, UAE : , : Bentham Science Publishers, , [2018] |
| Descrizione fisica | 1 online resource (218 pages) |
| Disciplina | 615.7 |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations |
| ISBN | 1-68108-607-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910809359503321 |
| Sharjah, UAE : , : Bentham Science Publishers, , [2018] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research . Volume 2 CNS and neurological disorders / / editor, Atta-ur-Rahman
| Frontiers in clinical drug research . Volume 2 CNS and neurological disorders / / editor, Atta-ur-Rahman |
| Pubbl/distr/stampa | Sharjah, U.A.E. ; ; Oak Park, Illinois : , : Bentham Science Publishers, , [2013] |
| Descrizione fisica | 1 online resource (373 p.) |
| Disciplina | 610.28 |
| Altri autori (Persone) | RahmanAtta-ur- <1942-> |
| Collana | Frontiers in clinical drug research |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations Pharmaceutical chemistry |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-60805-775-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Title; EUL; Contents; Foreword; Preface; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Index |
| Altri titoli varianti | CNS and neurological disorders |
| Record Nr. | UNINA-9910464654703321 |
| Sharjah, U.A.E. ; ; Oak Park, Illinois : , : Bentham Science Publishers, , [2013] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research . Volume 2 CNS and neurological disorders / / editor, Atta-ur-Rahman
| Frontiers in clinical drug research . Volume 2 CNS and neurological disorders / / editor, Atta-ur-Rahman |
| Pubbl/distr/stampa | Sharjah, U.A.E. ; ; Oak Park, Illinois : , : Bentham Science Publishers, , [2013] |
| Descrizione fisica | 1 online resource (373 p.) |
| Disciplina | 610.28 |
| Altri autori (Persone) | RahmanAtta-ur- <1942-> |
| Collana | Frontiers in clinical drug research |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations Pharmaceutical chemistry |
| ISBN | 1-60805-775-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Title; EUL; Contents; Foreword; Preface; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Index |
| Altri titoli varianti | CNS and neurological disorders |
| Record Nr. | UNINA-9910788935403321 |
| Sharjah, U.A.E. ; ; Oak Park, Illinois : , : Bentham Science Publishers, , [2013] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research . Volume 2 CNS and neurological disorders / / editor, Atta-ur-Rahman
| Frontiers in clinical drug research . Volume 2 CNS and neurological disorders / / editor, Atta-ur-Rahman |
| Pubbl/distr/stampa | Sharjah, U.A.E. ; ; Oak Park, Illinois : , : Bentham Science Publishers, , [2013] |
| Descrizione fisica | 1 online resource (373 p.) |
| Disciplina | 610.28 |
| Altri autori (Persone) | RahmanAtta-ur- <1942-> |
| Collana | Frontiers in clinical drug research |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations Pharmaceutical chemistry |
| ISBN | 1-60805-775-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Title; EUL; Contents; Foreword; Preface; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Index |
| Altri titoli varianti | CNS and neurological disorders |
| Record Nr. | UNINA-9910825560703321 |
| Sharjah, U.A.E. ; ; Oak Park, Illinois : , : Bentham Science Publishers, , [2013] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in Clinical Drug Research - Anti-Cancer Agents
| Frontiers in Clinical Drug Research - Anti-Cancer Agents |
| Autore | Atta-ur-Rahman |
| Pubbl/distr/stampa | Sharjah : , : Bentham Science Publishers, , 2016 |
| Descrizione fisica | 1 online resource (516 pages) |
| Disciplina | 615.7 |
| Collana | Frontiers in Clinical Drug Research - Anti-Cancer Agents |
| Soggetto topico |
Biopharmaceutics
Medical innovations Pharmaceutical chemistry Drugs--Design Antineoplastic agents Cancer - Alternative treatment |
| ISBN | 1-68108-289-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- CONTENTS -- PREFACE -- List of Contributors -- Tumor Resistance Mechanisms to Inhibitors Targeting the Epidermal Growth Factor Receptor- Part I: Extracellular Molecules -- 1. INTRODUCTION -- 2. LINKING THE EGFR WITH CANCER THERAPUTICS -- 3. THERAPEUTIC AGENTS TARGETING THE EGFR -- 3.1. Cetuximab/Erbitux (Bristol-Myers Squibb and Eli Lilly and Company) -- 3.2. Panitumumab/Vectibix (Amgen Inc) -- 3.3. Lapatinib/Tykerb (GlaxoSmithKline) -- 3.4. Gefitinib/Iressa (AstraZeneca) -- 3.5. Erlotinib/Tarceva (Genentech) -- 3.6. Afatinib/Gilotrif (Boehringer Ingelheim Pharmaceuticals) -- 4. BIOMARKERS PREDICTING SENSITIVITY AND RESISTANCE TO ANTI-EGFR THERAPIES - LIGANDS OF THE EGFR AS PREDICTORS OF RESPONSE TO ANTI-EGFR THERAPY -- 4.1. Amphiregulin (AREG) and Epiregulin (EREG) -- 4.2. Transforming Growth Factor Alpha (TGFα) -- 4.3. Epidermal Growth Factor (EGF) -- 4.4. Heparin-Binding EGF-LIKE Growth Factor (HB-EGF) -- 4.5. Betacellulin (BTC) and Epigen (EPGN) -- 5. BIOMARKERS PREDICTING SENSITIVITY AND RESISTANCE TO ANTI-EGFR THERAPIES - ALTERATIONS IN ERBB RECEPTORS FAMILY MEMBERS -- 5.1. Epidermal Growth Factor Receptor (EGFR) -- 5.1.1. EGFR Gene and Protein Expression -- 5.1.2. EGFR Gene Copy Number (GCN) -- 5.1.3. EGFR Mutations -- 5.2. HER2 (ErbB2) -- 5.3. HER3, HER4 and Neuregulins (NRG) -- 6. ALTERATIONS IN NON-ERBB RECEPTOR FAMILY MEMBERS -- 6.1. Hepatocyte Growth Factor/Scatter Factor (HGF)/MET -- 6.2. Insulin-like Growth Factor (IGF)/IGF-R -- 6.3. Fibroblast Growth Factor (FGF)/FGFR -- 6.4. Platelet-derived Growth Factor (PDGF)/PDGFR -- 6.5. Vascular Endothelial Growth Factor (VEGF)/VEGFR -- 6.6. GAS6/AXL -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Tumor Resistance Mechanisms to Inhibitors Targeting the Epidermal Growth Factor Receptor - Part II: Intracellular Molecules.
1. INTRODUCTION -- 2. INTRACELLULAR TRAFFICKING OF THE EGFR AND RESISTANCE TO ANTI-EGFR THERAPY -- 3. THE RAS/REF/MEK/ERK SIGNALING PATHWAY AND RESISTANCE TO ANTI-EGFR THERAPY -- 3.1. Growth Factor Receptor-bound Protein 2 (Grb2) -- 3.2. RAS -- 3.2.1. The Role of K-RAS in Primary Resistance -- 3.2.2. The Role of K-RAS in Acquired Resistance -- 3.3. RAF -- 3.4. MAPK Extracellular Signal-regulated Kinase (MEK) and Extracellular Signal-regulated Kinase (ERK1/2) -- 3.5. Dual-Specificity MAP Kinase Phosphatases (DUSPs) -- 4. THE PI3-K SIGNALING PATHWAY AND RESISTANCE TO ANTI-EGFR THERAPY -- 4.1. Phosphatidylinositol 3-kinase (PI3-K) -- 4.2. PTEN -- 5. ANALYSIS OF SEVERAL BIOMARKERS IN COMBINATION AND RESISTANCE TO ANTI-EGFR THERAPY -- 6. THE JAK/STAT SIGNALING PATHWAY AND RESISTANCE TO ANTI-EGFR THERAPY -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Chemotherapeutic, Immunologic, and Molecularly Targeted Therapy for the Treatment of Advanced Melanoma -- INTRODUCTION -- CHEMOTHERAPEUTIC AGENTS -- Alkylating Agents -- Dacarbazine -- Temozolomide -- Platinum Compounds -- Taxanes -- Nitrosureas -- Chemotherapy in Combination -- IMMUNOTHERAPY -- Interferon Alpha -- Interleukin-2 (IL-2) -- Vaccine Therapy -- Peptide Vaccines -- Adoptive Cell Therapy -- Immune Checkpoint Inhibitors -- Immune Checkpoint Inhibitors in Combination -- MOLECULARLY TARGETED THERAPY -- MAPK Signaling Pathway -- BRAF Inhibitors -- MEK Inhibitors -- C-KIT Inhibitors -- Molecularly Targeted Therapies in Combination -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Targeting the Warburg Effect for Cancer Therapy: A Long and Winding Road -- 1. THERAPEUTICAL APPROACHES TO CANCER: FROM CHEMOTHERAPY TO TARGETED THERAPIES -- 2. BIOENERGETICS: A VERY BRIEF OVERVIEW -- 3. THE WARBURG EFFECT: CURRENT PERSPECTIVE. 4. CURRENT AND PAST EFFORTS AT TARGETING THE WARBURG EFFECT FOR CANCER THERAPY -- CONCLUDING REMARKS -- NOTES -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Immunotherapy Strategies in Follicular Lymphoma: Antibodies, Vaccines and Cells -- 1. INTRODUCTION -- 2. BIOLOGY OF FOLLICULAR LYMPHOMA -- 2.1. Histopathology of FL -- 2.2. Follicular Lymphoma-cell Origin -- 2.3. Follicular Lymphoma Microenvironment -- 3. PREVIOUS CONSIDERATIONS BEFORE THERAPY -- 3.1. Who should be Treated, and When? -- 3.2. How to define Treatment Intensity -- 4. FIRST LINE TREATMENT -- 4.1. Early-stage Disease -- 4.2. Induction Treatment for Advanced Stages -- 4.3. Consolidation Treatment -- 4.3.1. Interferon Maintenance -- 4.3.2. Rituximab Maintenance -- 4.3.3. Autologous Stem-cell Transplantation -- 4.3.4. Radioimmunotherapy -- 5. RELAPSE TREATMENT -- 5.1. Choice of Rescue Treatment -- 5.2. Bortezomib for FL Relapse -- 5.3. Autologous Stem-cell Transplantation for FL Relapse -- 5.4. Radioimmunotherapy for FL Relapse -- 5.5. Rituximab Maintenance for FL Relapse -- 5.6. Role of Allogeneic SCT -- 6. NOVEL AND EMERGING PHARMACOLOGICAL AGENTS -- 7. INNOVATIVE IMMUNOTHERAPY STRATEGIES FOR TREATMENT OF FL -- 7.1. Passive Immunotherapy: Adoptive Cell Therapy -- 7.1.1. LAK Cells -- 7.1.2. NK Cells -- 7.1.3. Antigen-specific T Cells -- 7.1.4. Treatment Combinations: Rituximab and Effector Cells -- 7.2. Active Immunotherapy Strategies: Vaccines -- 7.2.1. Idiotype Protein Vaccines -- 7.2.2. DNA Vaccines -- 7.2.3. Dendritic Cell Vaccines -- 7.2.4. Membrane Proteoliposomal Vaccines -- 7.2.5. Strategies to Enhance Immunogenicity -- 7.3. New Targets for Immunotherapy -- 7.4. Future Directions in Vaccine Development -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES. Epigenetics and Cancer Cell Metabolism: Cross-talk and Therapeutic Opportunities -- INTRODUCTION -- CANCER EPIGENETICS AND ROLE IN CARCINOGENESIS -- DNA Methylation -- Histone Modifications -- Non-coding RNA -- CANCER METABOLISM -- The Warburg's Hypothesis: Deregulated Metabolism in Cancer -- Pathways Leading to Altered Metabolism in Tumors -- Epigenetics and Metabolism: Crosstalk -- MODULATION OF METABOLISM BY EPIGENETIC DYS-REGULATION -- Modulation of Metabolism by DNA Methylation -- Modulation of Metabolism by Histone Modifications -- Modulation of Metabolism by miRNAs -- EPIGENETIC REGULATION BY THE AVAILABILITY OF CO-SUBSTRATES -- Acetyl-CoA and Histone Acetylation -- S-adenosylmethionine and DNA and Histone Methylation -- EPIGENETIC DYSREGULATION INDUCED BY ONCOMETABOLITES -- 2-Hydroxylglutarate Production in IDH1 and IDH2 Mutant Cancers -- 2-Hydroxylglutarate Modulates DNA Methylation -- 2-Hydroxylglutarate Modulates Histone Methylation -- Succinate and Fumarate Modulate DNA and Histone Methylation -- THERAPEUTIC OPPORTUNITIES -- DNMT Inhibitors -- HDAC Inhibitors (HDACi) -- miRNA Targeting Agents -- IDH1 and IDH2 Inhibitors -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Apoptosis Targeting Therapeutics in Clinical Trials -- CANCER -- APOPTOSIS -- MECHANISMS OF APOPTOSIS -- TARGETING P53 -- p53-based Gene Therapy -- p53-based Immunotherapy -- p53-based Drug Therapy -- ANTI-APOPTOTIC PROTEINS -- Targeting the MDM2-p53 Complex -- Nutlins -- RG7112 -- MK-8242 and MI-888 -- MI-219 -- SAR405838 (MI-77301) -- CGM097 -- Other MDM2 Inhibitors -- Targeting the IAPs -- OGX-011 -- GDC-0152 and GDC-0917 (CUDC-427) (Genentech) -- AEG40826/HGS1029 (Aegera/Human Genome Sciences) -- LCL161 (Novartis) -- SM-406/AT-406/Debio 1143 (University of Michigan/Ascenta/DebioPharm) -- SM-164 -- LBW242 -- Other IAP Antagonists. Targeting the BCL Family of Proteins -- ABT-737 and ABT-263 (navitoclax) -- ABT-199 (GDC-0199/venetoclax, AbbVie) -- Obatoclax Mesylate (GX15-070) (Gemin X/Teva) -- AT-101 R-(−)-gossypol (Ascenta) -- OTHER APOPTOSIS INDUCERS [44] -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- SUBJECT INDEX. |
| Altri titoli varianti | Frontiers in Clinical Drug Research - Anti-Cancer Agents |
| Record Nr. | UNINA-9910156229203321 |
Atta-ur-Rahman
|
||
| Sharjah : , : Bentham Science Publishers, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research - anti-cancer agents . Volume 5 / / edited by Atta-ur-Rahman
| Frontiers in clinical drug research - anti-cancer agents . Volume 5 / / edited by Atta-ur-Rahman |
| Pubbl/distr/stampa | Singapore : , : Bentham Books, , [2019] |
| Descrizione fisica | 1 online resource (187 pages) |
| Disciplina | 615.7 |
| Soggetto topico | Biopharmaceutics |
| ISBN | 981-14-0515-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910793819803321 |
| Singapore : , : Bentham Books, , [2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research - anti-cancer agents . Volume 5 / / edited by Atta-ur-Rahman
| Frontiers in clinical drug research - anti-cancer agents . Volume 5 / / edited by Atta-ur-Rahman |
| Pubbl/distr/stampa | Singapore : , : Bentham Books, , [2019] |
| Descrizione fisica | 1 online resource (187 pages) |
| Disciplina | 615.7 |
| Soggetto topico | Biopharmaceutics |
| ISBN | 981-14-0515-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910821680403321 |
| Singapore : , : Bentham Books, , [2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Biopharmaceutics
(106)
- Pharmacology (21)
- Pharmaceutical chemistry (19)
- Drugs - Design (16)
- Drug development (14)